Blood and breath profiles of volatile organic compounds in patients with end-stage renal disease

BMC Nephrology

Volumn 15, Issue 1, 2014, Pages 1-14

  Mochalski, Paweł ^a,b   King, Julian ^a   Haas, Matthias ^a   Unterkofler, Karl ^a   Amann, Anton ^a,c   Mayer, Gert ^c  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b INSTITUTE OF NUCLEAR PHYSICS   (Poland)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Blood analysis; Breath analysis; End stage renal disease; Hemodialysis; Uremic syndrome; Volatile organic compounds

Indexed keywords

ALDEHYDE; BENZENE; BIOLOGICAL MARKER; DIMETHYL SULFIDE; HETEROCYCLIC COMPOUND; HYDROCARBON; ISOPRENE; KETONE; METHYL PROPYL SULFIDE; PROPANE; SULFUR; TERPENE; THIOPHENE; UNCLASSIFIED DRUG; UREMIC TOXIN; VOLATILE ORGANIC COMPOUND; ALLYL METHYL SULFIDE; CYCLOHEXANONE; SULFIDE; TERPENE DERIVATIVE;

ADULT; ADVERSE DRUG REACTION; AGED; AIR POLLUTANT; ANALYTIC METHOD; ARTICLE; BLOOD ANALYSIS; BREATH ANALYSIS; BREATHING; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; END STAGE RENAL DISEASE; ETIOLOGY; EXHALATION; FEMALE; GAS CHROMATOGRAPHY; HEMODIALYSIS; HUMAN; LUNG GAS EXCHANGE; MALE; MASS SPECTROMETRY; METABOLISM; RENAL REPLACEMENT THERAPY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SOLID PHASE MICROEXTRACTION; THERAPY; TREATMENT OUTCOME; UREMIA; UREMIC BREATH; CHILD; INFANT;

ADULT; ADVERSE EFFECTS; AGED; BIOLOGICAL MARKERS; BREATH TESTS; ETIOLOGY; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; METABOLISM; RENAL DIALYSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THERAPY; TREATMENT OUTCOME; UREMIA; VOLATILE ORGANIC COMPOUNDS;

EID: 84897404078     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-15-43     Document Type: Article

References (44)

1. NKF KDOQI GUIDELINES. Anonymous, http://www.kidney.org/professionals/ KDOQI/guideline-upHD-PD-VA/hd-rec2.htm, downloaded Mar 3, 2013
2. Normal and pathologic concentrations of uremic toxins. Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A, J Am Soc Nephrol 2012 23 1258 1270 10.1681/ASN.2011121175 22626821
3. Lung cancer biomarkers in exhaled breath. Amann A, Corradi M, Mazzone P, Mutti A, Expert Rev Mol Diagn 2011 11 207 217 10.1586/erm.10.112 21405971
4. Amann A, Smith D, Breath analysis for clinical diagnosis and therapeutic monitoring New Jersey: World Scientific 2005
5. Diagnostic potential of breath analysis-focus on volatile organic compounds. Miekisch W, Schubert JK, Noeldge-Schomburg GF, Clin Chim Acta 2004 347 25 39 10.1016/j.cccn.2004.04.023 15313139 (Pubitemid 39099603)
6. Noninvasive detection of lung cancer by analysis of exhaled breath. Bajtarevic A, Ager C, Pienz M, Klieber M, Schwarz K, Ligor M, Ligor T, Filipiak W, Denz H, Fiegl M, Hilbe W, Weiss W, Lukas P, Jamnig H, Hackl M, Haidenberger A, Buszewski B, Miekisch W, Schubert J, Amann A, BMC Cancer 2009 9 348 10.1186/1471-2407-9-348 19788722
7. Detection of lung cancer using weighted digital analysis of breath biomarkers. Phillips M, Altorki N, Austin JH, Cameron RB, Cataneo RN, Kloss R, Maxfield RA, Munawar MI, Pass HI, Rashid A, Rom WN, Schmitt P, Wai J, Clin Chim Acta 2008 393 76 84 10.1016/j.cca.2008.02.021 18420034
8. Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study. Poli D, Carbognani P, Corradi M, Goldoni M, Acampa O, Balbi B, Bianchi L, Rusca M, Mutti A, Respir Res 2005 6 71 10.1186/1465-9921-6-71 16018807 (Pubitemid 41410164)
9. Biochemical profile or uremic breath. Simenhoff ML, Burke JF, Saukkonen JJ, Ordinario AT, Doty R, N Engl J Med 1977 297 132 135 10.1056/ NEJM197707212970303 865584
10. Breath ammonia and trimethylamine allow real-time monitoring of haemodialysis efficacy. Endre ZH, Pickering JW, Storer MK, Hu WP, Moorhead KT, Allardyce R, McGregor DO, Scotter JM, Physiol Meas 2011 32 115 130 10.1088/0967-3334/32/1/008 21149927
11. The breath ammonia measurement of the hemodialysis with a QCM-NH3 sensor. Ishida H, Satou T, Tsuji K, Kawashima N, Takemura H, Kosaki Y, Shiratori S, Agishi T, Biomed Mater Eng 2008 18 99 106 18408261 (Pubitemid 352040124)
12. Correlation of breath ammonia with blood urea nitrogen and creatinine during hemodialysis. Narasimhan LR, Goodman W, Patel CK, Proc Natl Acad Sci U S A 2001 98 4617 4621 10.1073/pnas.071057598 11296293 (Pubitemid 32295025)
13. Breath analysis in patients with end-stage renal disease: effect of haemodialysis. Rolla G, Bruno M, Bommarito L, Heffler E, Ferrero N, Petrarulo M, Bagnis C, Bugiani M, Guida G, Eur J Clin Invest 2008 38 728 733 10.1111/j.1365-2362.2008.02016.x 18837798
14. Quantitative analysis of ammonia on the breath of patients in end-stage renal failure. Davies S, Spanel P, Smith D, Kidney Int 1997 52 223 228 10.1038/ki.1997.324 9211367 (Pubitemid 27321835)
15. Dynamic study of oxidative stress in renal dialysis patients based on breath ethane measured by optical spectroscopy. Patterson CS, McMillan LC, Stevenson K, Radhakrishnan K, Shiels PG, Padgett MJ, Skeldon KD, J Breath Res 2007 1 026005 10.1088/1752-7155/1/2/026005 21383439
16. Breath ethane peaks during a single haemodialysis session and is associated with time on dialysis. Stevenson KS, Radhakrishnan K, Patterson CS, McMillan LC, Skeldon KD, Buist L, Padgett MJ, Shiels PG, J Breath Res 2008 2 026004 10.1088/1752-7155/2/2/026004 21383445 (Pubitemid 352000634)
17. Breath ethane in dialysis patients and control subjects. Handelman GJ, Rosales LM, Barbato D, Luscher J, Adhikarla R, Nicolosi RJ, Finkelstein FO, Ronco C, Kaysen GA, Hoenich NA, Levin NW, Free Radic Biol Med 2003 35 17 23 10.1016/S0891-5849(03)00183-7 12826252 (Pubitemid 36789764)
18. Effect of two-hour daily hemodialysis and sham dialysis on breath isoprene exhalation. Capodicasa E, Brunori F, De Medio GE, Pelli MA, Vecchi L, Buoncristiani U, Int J Artif Organs 2007 30 583 588 17674334 (Pubitemid 47455587)
19. Onset, time course, and persistence of increased haemodialysis-induced breath isoprene emission. Trovarelli G, Brunori F, De Medio GE, Timio M, Lippi G, Pelli MA, Capodicasa E, Nephron 2001 88 44 47 10.1159/000045958 11340350 (Pubitemid 32429702)
20. Volatile alkanes and increased concentrations of isoprene in exhaled air during hemodialysis. Capodicasa E, Trovarelli G, De Medio GE, Pelli MA, Lippi G, Verdura C, Timio M, Nephron 1999 82 331 337 10.1159/000045448 10450035 (Pubitemid 29385305)
21. Elective haemodialysis increases exhaled isoprene. Lirk P, Bodrogi F, Raifer H, Greiner K, Ulmer H, Rieder J, Nephrol Dial Transplant 2003 18 937 941 10.1093/ndt/gfg049 12686668 (Pubitemid 36592536)
22. A new 'online' method to measure increased exhaled isoprene in end-stage renal failure. Davies S, Spanel P, Smith D, Nephrol Dial Transplant 2001 16 836 839 10.1093/ndt/16.4.836 11274283 (Pubitemid 32257985)
23. Lack of isoprene overproduction during peritoneal dialysis. Capodicasa E, Trovarelli G, Brunori F, Vecchi L, Carobi C, De M, Pelli MA, Buoncristiani U, Perit Dial Int 2002 22 48 52 11929143 (Pubitemid 34326579)
24. Exposure to potentially toxic hydrocarbons and halocarbons released from the dialyzer and tubing set during hemodialysis. Lee HJ, Meinardi S, Pahl MV, Vaziri ND, Blake DR, Am J Kidney Dis 2012 60 609 616 10.1053/j.ajkd.2012.02.327 22507911
25. Blood and breath levels of selected volatile organic compounds in healthy volunteers. Mochalski P, King J, Klieber M, Unterkofler K, Hinterhuber H, Baumann M, Amann A, Analyst 2013 138 2134 2145 10.1039/c3an36756h 23435188
26. Methodological issues of sample collection and analysis of exhaled breath. Amann A, Miekisch W, Pleil J, Risby T, Schubert J, Eur Respir Mon 2010 49 96 114
27. Stability of selected volatile breath constituents in Tedlar, Kynar and Flexfilm sampling bags. Mochalski P, King J, Unterkofler K, Amann A, Analyst 2013 138 1405 1418 10.1039/c2an36193k 23323261
28. Dynamic profiles of volatile organic compounds in exhaled breath as determined by a coupled PTR-MS/GC-MS study. King J, Mochalski P, Kupferthaler A, Unterkofler K, Koc H, Filipiak W, Teschl S, Hinterhuber H, Amann A, Physiol Meas 2010 31 1169 1184 10.1088/0967-3334/31/9/008 20664160
29. Volatile breath biomarkers for patient monitoring during haemodialysis. Goerl T, Kischkel S, Sawacki A, Fuchs P, Miekisch W, Schubert JK, J Breath Res 2013 7 017116 10.1088/1752-7155/7/1/017116 23446309
30. Temporal profiling of human urine VOCs and its potential role under the ruins of collapsed buildings. Mochalski P, Krapf K, Ager C, Wiesenhofer H, Agapiou A, Statheropoulos M, Fuchs D, Ellmerer E, Buszewski B, Amann A, Toxicol Mech Methods 2012 22 502 511 10.3109/15376516.2012.682664 22482743
31. Potential applications of breath isoprene as a biomarker in modern medicine: a concise overview. Salerno-Kennedy R, Cashman KD, Wien Klin Wochenschr 2005 117 180 186 10.1007/s00508-005-0336-9 15875756 (Pubitemid 40645909)
32. Isoprene synthesis by plants and animals. Sharkey TD, Endeavour 1996 20 74 78 10.1016/0160-9327(96)10014-4 8690002 (Pubitemid 27111666)
33. Enzymatic synthesis of isoprene from dimethylallyl diphosphate in aspen leaf extracts. Silver GM, Fall R, Plant Physiol 1991 97 1588 1591 10.1104/pp.97.4.1588 16668590 (Pubitemid 21914407)
34. Analysis of volatile disease markers in blood. Miekisch W, Schubert JK, Vagts DA, Geiger K, Clin Chem 2001 47 1053 1060 11375291 (Pubitemid 32493591)
35. Analysis of volatile organic compounds in human urine by headspace gas chromatography-mass spectrometry with a multipurpose sampler. Wahl HG, Hoffmann A, Luft D, Liebich HM, J Chromatogr A 1999 847 117 125 10.1016/S0021-9673(99) 00017-5 10431355 (Pubitemid 29306881)
36. Headspace solid-phase microextraction profiling of volatile compounds in urine: application to metabolic investigations. Mills GA, Walker V, J Chromatogr B Biomed Sci Appl 2001 753 259 268 10.1016/S0378-4347(00)00554-5 11334339 (Pubitemid 32217725)
37. 4-Heptanone is a metabolite of the plasticizer di(2-ethylhexyl) phthalate (DEHP) in haemodialysis patients. Wahl HG, Hong Q, Hildenbrand S, Risler T, Luft D, Liebich H, Nephrol Dial Transplant 2004 19 2576 2583 10.1093/ndt/gfh425 15280519 (Pubitemid 39360107)
38. Urine 4-heptanone: a beta-oxidation product of 2-ethylhexanoic acid from plasticisers. Walker V, Mills GA, Clin Chim Acta 2001 306 51 61 10.1016/S0009-8981(01)00390-4 11282094 (Pubitemid 32244325)
39. Cyclohexanone contamination from extracorporeal circuits impairs cardiovascular function. Thompson-Torgerson CS, Champion HC, Santhanam L, Harris ZL, Shoukas AA, Am J Physiol Heart Circ Physiol 2009 296 1926 H1932 10.1152/ajpheart.00184.2009 19411286
40. Increase in putrescine, amine oxidase, and acrolein in plasma of renal failure patients. Sakata K, Kashiwagi K, Sharmin S, Ueda S, Irie Y, Murotani N, Igarashi K, Biochem Biophys Res Comm 2003 305 143 149 10.1016/S0006-291X(03) 00716-2 12732208 (Pubitemid 36535419)
41. Gas chromatography-mass spectrometric analysis of hexanal and heptanal in human blood by headspace single-drop microextraction with droplet derivatization. Li N, Deng C, Yin X, Yao N, Shen X, Zhang X, Anal Biochem 2005 342 318 326 10.1016/j.ab.2005.04.024 15913536 (Pubitemid 40884582)
42. TD-GC-MS analysis of volatile metabolites of human lung cancer and normal cells in vitro. Filipiak W, Sponring A, Filipiak A, Ager C, Schubert J, Miekisch W, Amann A, Troppmair J, Cancer Epidemiol Biomarkers Prev 2010 19 182 195 10.1158/1055-9965.EPI-09-0162 20056637
43. Analysis of volatile organic compounds (VOCs) in the headspace of NCI-H1666 lung cancer cells. Sponring A, Filipiak W, Ager C, Schubert J, Miekisch W, Amann A, Troppmair J, Cancer Biomark 2010 7 153 161 21263191
44. Efficiency of hemodialysis of pyrimidine compounds in patients with chronic renal failure. Daniewska-Michalska D, Motyl T, Gellert R, Kukulska W, Podgurniak M, Opechowska-Pacocha E, Ostrowski K, Nephron 1993 64 193 197 10.1159/000187313 8321350 (Pubitemid 23153045)